APELLIS PHARMACEUTICALS INC. - COMMON STOCK
28.25
13-November-24 16:45:00
15 minutes delayed
Stocks
-1.01
-3.45%
Today's range
28.23 - 29.94
ISIN
N/A
Source
NASDAQ
-
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
07 May 2024 07:05:00 By Nasdaq GlobeNewswire
-
06 May 2024 07:00:00 By Nasdaq GlobeNewswire
-
01 May 2024 07:00:00 By Nasdaq GlobeNewswire
-
26 Apr 2024 07:15:00 By Nasdaq GlobeNewswire
-
23 Apr 2024 07:00:14 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 16:05:00 By Nasdaq GlobeNewswire
-
01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
-
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2024 16:05:00 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 07:05:00 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire
-
26 Jan 2024 07:06:23 By Nasdaq GlobeNewswire
-
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
08 Jan 2024 09:00:00 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 16:05:00 By Nasdaq GlobeNewswire
-
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
-
28 Dec 2023 07:00:00 By Nasdaq GlobeNewswire
-
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
14 Dec 2023 07:00:00 By Nasdaq GlobeNewswire
-
11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire